Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26694043 | 0.84 | DGAT1 (0.40) | KEAP1KDM4EGLAHDAC1HDAC6 | |
| SCHEMBL17007116 | 0.83 | CES2 (0.41) | KDM4ETDP1CES2CES1DGAT1 | |
| SCHEMBL27575206 | 0.83 | KDM4E (0.47) | KEAP1KDM4EGLAKMT2AGFER | |
| SCHEMBL21750024 | 0.81 | KEAP1 (0.45) | KEAP1KDM4EGLAHDAC1HDAC6 | |
| SCHEMBL7823717 | 0.79 | KDM4E (0.44) | KEAP1KDM4EGLAKMT2AGFER | |
| SCHEMBL2203971 | 0.79 | KEAP1 (0.44) | KEAP1KDM4EGLAHDAC1HDAC6 | |
| SCHEMBL8178102 | 0.78 | ALDH1A1 (0.41) | KDM4EGLAHDAC1HDAC6KMT2A | |
| SCHEMBL24717969 | 0.78 | CYP1A2 (0.41) | KEAP1KDM4EGLAALDH1A1CES2 | |
| SCHEMBL25679318 | 0.78 | CA1 (0.46) | KDM4EKMT2APOLBMEN1MAPT | |
| SCHEMBL24753003 | 0.78 | KDM4E (0.42) | KEAP1KDM4EGLAKMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-114685395-A | 2, 3-dihydrobenzo [ d ] isothiazole compound and application thereof | 浙江大学 | 2022-07-01 | — | — | CN | disclosed |
| EP-3024827-B1 | SUBSTITUTED QUINAZOLIN-4-ONE DERIVATIVES | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| US-9840498-B2 | Substituted quinazolin-4-one derivatives | NOVARTIS AG (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9840498-B2 | Substituted quinazolin-4-one derivatives | NOVARTIS AG (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9840498-B2 | Substituted quinazolin-4-one derivatives | NOVARTIS AG (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20160168131-A1 | Substituted Quinazolin-4-one Derivatives | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-20160168131-A1 | Substituted Quinazolin-4-one Derivatives | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-20160168131-A1 | Substituted Quinazolin-4-one Derivatives | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| EP-3024827-A1 | SUBSTITUTED QUINAZOLIN-4-ONE DERIVATIVES | Novartis AG (CH) | 2016-06-01 | — | — | EP | disclosed |
| CN-105452235-A | Substituted quinazolin-4-one derivatives | NOVARTIS AG | 2016-03-30 | — | — | CN | disclosed |
| WO-2015010641-A1 | SUBSTITUTED QUINAZOLIN-4-ONE DERIVATIVES | NOVARTIS AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015010641-A1 | SUBSTITUTED QUINAZOLIN-4-ONE DERIVATIVES | NOVARTIS AG (CH) | 2015-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168131-A1 | Substituted Quinazolin-4-one Derivatives | PIK3CA, AKT3, PIK3CD | KEAP1 1989/4885KDM4E 2808/4885GLA 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.